JP7378739B2 - 前立腺がんの検出のためのキット、デバイス及び方法 - Google Patents

前立腺がんの検出のためのキット、デバイス及び方法 Download PDF

Info

Publication number
JP7378739B2
JP7378739B2 JP2020535900A JP2020535900A JP7378739B2 JP 7378739 B2 JP7378739 B2 JP 7378739B2 JP 2020535900 A JP2020535900 A JP 2020535900A JP 2020535900 A JP2020535900 A JP 2020535900A JP 7378739 B2 JP7378739 B2 JP 7378739B2
Authority
JP
Japan
Prior art keywords
polynucleotide
base sequence
prostate cancer
mir
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020535900A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020032228A1 (ja
JPWO2020032228A5 (https=
Inventor
真紀子 吉本
裕子 須藤
敦子 宮野
聡子 小園
孝広 落谷
博行 藤元
文彦 占部
潤太郎 松▲崎▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
National Cancer Center Japan
Original Assignee
Toray Industries Inc
National Cancer Center Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc, National Cancer Center Japan filed Critical Toray Industries Inc
Publication of JPWO2020032228A1 publication Critical patent/JPWO2020032228A1/ja
Publication of JPWO2020032228A5 publication Critical patent/JPWO2020032228A5/ja
Application granted granted Critical
Publication of JP7378739B2 publication Critical patent/JP7378739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020535900A 2018-08-10 2019-08-09 前立腺がんの検出のためのキット、デバイス及び方法 Active JP7378739B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018151952 2018-08-10
JP2018151952 2018-08-10
PCT/JP2019/031550 WO2020032228A1 (ja) 2018-08-10 2019-08-09 前立腺がんの検出のためのキット、デバイス及び方法

Publications (3)

Publication Number Publication Date
JPWO2020032228A1 JPWO2020032228A1 (ja) 2021-08-26
JPWO2020032228A5 JPWO2020032228A5 (https=) 2022-07-27
JP7378739B2 true JP7378739B2 (ja) 2023-11-14

Family

ID=69414816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020535900A Active JP7378739B2 (ja) 2018-08-10 2019-08-09 前立腺がんの検出のためのキット、デバイス及び方法

Country Status (4)

Country Link
US (3) US11535899B2 (https=)
EP (1) EP3835434A4 (https=)
JP (1) JP7378739B2 (https=)
WO (1) WO2020032228A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12237082B2 (en) * 2020-12-31 2025-02-25 Flatiron Health, Inc. Clinical trial matching system using inferred biomarker status
EP4382618A4 (en) * 2021-08-02 2025-11-12 Medical Ark Inc CANINE CANCER DIAGNOSTIC METHOD
CN115838783A (zh) * 2022-08-29 2023-03-24 郑州大学 一种β-CD作为增强剂的PGM检测miR-21试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015194615A1 (ja) 2014-06-18 2015-12-23 東レ株式会社 肝臓がんの検出キット又はデバイス及び検出方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969147B1 (en) * 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
CN102027129B (zh) 2008-02-28 2014-03-12 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010054386A2 (en) 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
EP2634266B1 (en) * 2009-05-22 2015-10-14 Asuragen, INC. miRNA biomarkers of prostate disease
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
JPWO2012063894A1 (ja) * 2010-11-12 2014-05-12 国立大学法人愛媛大学 マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
KR20140067001A (ko) 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
WO2014071226A1 (en) 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
WO2014071205A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US9416369B2 (en) * 2012-12-18 2016-08-16 University Of Washington Through Its Center For Commercialization Methods and compositions to modulate RNA processing
JP2015039365A (ja) 2013-08-23 2015-03-02 東レ株式会社 前立腺がんの検出用キットおよび検出方法
CA2945531C (en) * 2014-05-13 2018-01-30 Zohar BARNETT-ITZHAKI Mirna expression signature in the classification of thyroid tumors
KR102761162B1 (ko) * 2014-06-12 2025-02-03 국립연구개발법인 고쿠리츠간켄큐센터 전립선암 검출 키트 또는 디바이스 및 검출 방법
BR112016029583A2 (pt) * 2014-06-18 2017-10-24 Nat Cancer Ct ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
WO2016081941A1 (en) 2014-11-21 2016-05-26 Caris Science, Inc. Oligonucleotide probes and uses thereof
KR101862080B1 (ko) 2015-02-25 2018-07-04 (주)바이오니아 마이크로 rna 를 유효 성분으로 포함하는 암 치료용 약학 조성물
KR101569370B1 (ko) 2015-05-27 2015-11-16 강건희 유무선 전화 수신환경 설정시스템.
JP6816577B2 (ja) 2017-03-14 2021-01-20 オムロン株式会社 リーダ装置、無線タグ、情報提示システム
JP7165329B2 (ja) * 2017-04-28 2022-11-04 東レ株式会社 卵巣腫瘍の検出のためのキット、デバイス及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015194615A1 (ja) 2014-06-18 2015-12-23 東レ株式会社 肝臓がんの検出キット又はデバイス及び検出方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oncotarget，2012年11月30日，Vol.3/No.11，P.1455-1471
URABE, Fumihiko et. al.，Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer.，Clinical cancer research，2019年05月15日，Vol.25, No.10，pp.3016-3025，特にFigure 1.D

Also Published As

Publication number Publication date
US11905565B2 (en) 2024-02-20
EP3835434A4 (en) 2022-06-08
JPWO2020032228A1 (ja) 2021-08-26
US20230212687A1 (en) 2023-07-06
US12252748B2 (en) 2025-03-18
WO2020032228A1 (ja) 2020-02-13
EP3835434A1 (en) 2021-06-16
US20240141439A1 (en) 2024-05-02
US20210310077A1 (en) 2021-10-07
US11535899B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
JP7448144B2 (ja) 前立腺がんの検出キット又はデバイス及び検出方法
CN106661619B (zh) 大肠癌的检测试剂盒或装置以及检测方法
CN106414774B (zh) 胆道癌的检测试剂盒或装置以及检测方法
EP3862439B1 (en) Liver cancer detection kit or device, and detection method
JP6797017B2 (ja) 膵臓がんの検出キット又はデバイス及び検出方法
CN110546263B (zh) 用于检测卵巢肿瘤的试剂盒、装置和方法
JP6925125B2 (ja) 胃がんの検出キット又はデバイス及び検出方法
US12252748B2 (en) Kit, device and method for detecting prostate cancer
CN112020566B (zh) 用于膀胱癌的检测的试剂盒、器件和方法
JP6611411B2 (ja) 膵臓がんの検出キット及び検出方法
US20190112668A1 (en) Kit or device for detecting malignant brain tumor and method for detecting same
JP6383541B2 (ja) 胆管がんの検出キット及び検出方法
EP4421171A1 (en) Kit, device and method for distinguishing between ovarian cancer and benign ovarian tumors
EP3936614A1 (en) Kit, device, and method for detecting uterine leiomyosarcoma
JP6103866B2 (ja) 大腸ガン検出方法、診断用キット及びｄｎａチップ
JP2020080773A (ja) ニボルマブ薬効予測のためのキット及び方法
JP2018074938A (ja) 悪性骨軟部腫瘍の検出用キット又はデバイス及び検出方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231024

R150 Certificate of patent or registration of utility model

Ref document number: 7378739

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150